Sentrx Growth Continues with Four New Clients in Second Quarter

Share Article

Sentrx, a leading provider of drug safety services, gained four new contracts in the second quarter, including a risk evaluation and mitigation strategy (REMS). The company was also awarded a significant contract expansion.

Drug Safety and Pharmacovigilance

Our unique blend of information technology talent, operational excellence and good clinical practices continues to meet the needs of the biopharmaceutical market.

Sentrx, a leading provider of drug safety services, announced today that the company signed four new multi-year contracts in the second quarter of 2008. Combined with wins from the first quarter, Sentrx gained nine clients in the first six months of 2008.

Sentrx pioneered the concept of drug safety outsourcing for clinical trial safety monitoring, post-marketing safety surveillance, and risk management programs. The multi-year contracts initiated in the second quarter of 2008 include:

  • A risk evaluation and mitigation strategy (REMS) for a biopharmaceutical company
  • Post-marketing safety surveillance with managed safety system hosting for a specialty pharmaceutical company
  • Clinical trial safety monitoring with managed safety system hosting for two biopharmaceutical companies

In addition to the new contracts, Sentrx was awarded a significant contract expansion from an existing large biopharmaceutical client. Sentrx will perform adverse event case processing for additional post-marketed products, doubling the volume of work in 2008.

Sentrx went live with one of the first FDA-required REMS implementations in July, meeting the client's extremely tight timeframe for successful product launch. The Sentrx SafetyTrak® Technology Suite was configured to create a controlled distribution program, ensuring that only registered hospitals order and receive the new drug. Health care professionals in the Sentrx Safety Response Center register hospitals that wish to utilize the treatment in certain post-surgical patients.

"Our second quarter results contain more than one milestone. Besides supporting one of the first REMS, Sentrx will be implementing its first Empirica(tm) Trace instance for a client, making us the only drug safety services provider to offer a choice of pharmacovigilance systems," said Joseph Albano, Chief Executive Officer of Sentrx. "Our unique blend of information technology talent, operational excellence and good clinical practices continues to meet the needs of the biopharmaceutical market."

About Sentrx:
Sentrx is a leading provider of technology-enabled solutions and services for global drug safety. Its mission is to help pharmaceutical, biotechnology, medical device, and consumer health companies document the safety profile of their products during clinical development and post-approval, enabling them to minimize risks and maximize benefits. Through its multilingual Safety Response Center, Sentrx delivers a unique combination of highly skilled people, exclusive technology, and best practices in drug safety monitoring. To learn more about Sentrx, please call 1-888-399-8032, extension 261, or click here for a short movie: (http://www.sentrx.com/impactmovie).

Media Contact:
Jill Notte
Executive Director, Marketing
150 Clove Road
Little Falls, NJ 07424
1-973-812-7575 ext. 261
http://www.sentrx.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jon Buschlen
Sentrx
1-888-399-8032
Email >
Visit website